Apollomics Inc(APLM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -7.57 | Insider Own | 57.41% | Shs Outstand | 2.9M | Perf Week | -10.97% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | - | Insider Trans | 53.51% | Shs Float | 1.2M | Perf Month | -17.68% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 0.37% | Short Float | 0.44% | Perf Quarter | 12.3% |
| Income | -0.01B | P/S | 6.73 | EPS this Y | - | Inst Trans | 85.5% | Short Ratio | 0.31 | Perf Half Y | 52.76% |
| Sales | 0.01B | P/B | - | EPS next 5Y | - | ROA | -110.43% | Short Interest | 0.01M | Perf YTD | 5% |
| Book/sh | - | P/C | 17.45 | EPS past 3/5Y | 50.29% 18.23% | ROE | -1305.37% | 52W High | -30.61% ($28.29) | Perf Year | -14.65% |
| Cash/sh | 1.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 96.19% ($10.01) | Perf 3Y | -77.23% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 86.1% | Gross Margin | - | Volatility(W/M) | 6.92% 5.66% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.5 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | -1224.24% | Profit Margin | -128.69% | RSI (14) | 36.12 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.96 | Sales Q/Q | - | SMA20 | -10.99% ($22.05) | Beta | 1.55 | Target Price | $50 |
| Payout | - | Debt/Eq | - | Earnings | 2026/4/27 | SMA50 | -15.84% ($23.32) | Rel Volume | 0.03 | Prev Close | $19.9 |
| Employees | 14 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 3.27% ($19.01) | Avg Volume(3M) | 0.02M | Price | $19.63 |
| IPO | 2021/11/26 | Option/Short | No/Yes | Trades | 72 | Volume | 519 | Change | -1.36% |
🧬 This is a clinical-stage oncology biotech developing cancer therapeutics targeting non-small cell lung cancer, brain tumors, and solid tumors. Its lead pipeline asset is <b>vebreltinib (APL-101)</b>, an oral selective c-MET inhibitor that has received FDA Orphan Drug Designation for NSCLC with MET gene alterations. In 2025, the company is navigating a restructuring phase — including restructuring efforts, new fundraising, and management changes — to keep its pipeline moving forward, making it a micro-cap biotech.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded less than usual. That is 3% of its average volume.
APLM has weak earning power
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $673. Peers typically go for $1,034.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be -77.2%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.4%.
Tap to view numbers
It ranks #402 of 594 in the industry
Based on market cap of $57M.
OSTX#400 OS Therapies Inc $58M PER - 
HRTX#401 Heron Therapeutics Inc $57M PER - APLM#402 Apollomics Inc $57M PER - 
CLNN#403 Clene Inc $56M PER - 
XBIT#404 XBiotech Inc $56M PER - 
FAQ
What kind of company is APLM?
APLM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of APLM?
The market cap of APLM is approximately $57M, ranking 4,772 within its sector.
What is the 52-week high and low for APLM?
APLM has recorded a 52-week high of $28.29 and a low of $10.01.
